It comprises two operational divisions dedicated to serve the pharmaceutical industry: Pharmaceutical Systems with …
Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington …
However, Buffett said he doesn't believe those stock purchases were illegal ... Jaffray Is A Market Maker In (ACOR), (ACRX), (CEPH), (DRRX), (ENDP), (IPXL), (ISPH), (OMPI), (PCRX), (SHPGY), (SLXP), (SNTS), (SOMX), (TEVA), …
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical Products, …
Dr. Obagi and Stonington received approximately $3,288 and $17,863 for 18,375 and 99,840 shares of Series A preferred stock and the related accrued ... This excerpt taken from the OMPI 10-K filed Mar 15, 2007. Stonington Capital …
OMPI: Summary for Obagi Medical Products,… View the basic OMPI stock chart on Yahoo! Finance. Change the date range, chart type and compare Obagi Medical Products, Inc. against other companies. Fidelity Health Care Fidelity …
Inc. (OMPI) 4/25/2013 11:21:05 AM Valeant Pharmaceuticals International (VRX) Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical …
Obagi (Nasdaq:OMPI) said its board of directors unanimously approved the ... rising $2.33 to US$25.21 on Nasdaq. On the Toronto Stock Exchange, Valeant’s shares fell $2.31 or three per cent, to C$74.17.
today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding …
The PEG Ratio can calculate if a stock is undervalued relative to its expected future ... MTW), Obagi Medical Products, …